Hoth Therapeutics (NASDAQ: HOTH) was on an upward trajectory in morning trading on Monday as the biopharmaceutical company announced positive data for BioLexa in a Phase 1b clinical trial.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
BioLexa is an investigational therapeutic in adult patients with mild-to-moderate atopic dermatitis.
BioLexa indicated a significant improvement in the severity of the disease as measured by SCORAD (SCORing Atopic Dermatitis) and EASI scale. The SCORAD scale measures the severity of atopic dermatitis.
Using the EASI scale, “100% of patients showed clinically relevant improvement >50% compared to Day 1 during the entire 28-day study treatment period.”